Kim TW, Kim DM. Effects of 0.5% apraclonidine on optic nerve head and peripapillary retinal blood flow. Br J Ophthalmol. 1997;81:1070-1072. Araujo SV, Bond JB, Wilson RP, et al. Long term effect of apraclonidine. Br J Ophthalmol. 1995;79:1098-1101.

Butler P, Mannschreck M, Lin S, et al. Clinical experience with the long-term use of 1% apraclonidine: incidence of allergic reactions. Arch Ophthalmol. 1995;113:293-296.

Nagasubramanian S, Hitchings RA, Demailly P, et al. Comparison of apraclonidine and timolol in chronic open-angle glaucoma: a three-month study. Ophthalmology. 1993;100:1318-1323.

Stewart WC, Ritch R, Shin DH, et al. The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group. Arch Ophthalmol. 1995;113:287-292.

Robin AL, Ritch R, Shin DH, et al. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group. Am J Ophthalmol. 1995;120:423-432. Thompson CD, Macdonald TL, Garst ME, et al. Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation. Exp Eye Res. 1997;64:767-773.

Gaasterland D, Kupfer C. Experimental glaucoma in the rhesus monkey. Invest Ophthalmol. 1974;13:455-457.

Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma: a pilot study. Arch Ophthalmol. 1979;97:319-322.

Pollack IP, Patz A. Argon laser iridotomy: an experimental and clinical study. Ophthalmic Surg. 1976;7:22-30.

Weinreb RN, Ruderman J, Juster R, Zweig K. Immediate intraocular pressure response to argon laser trabeculoplasty. Am J Ophthalmol. 1983;95:279-286. Glaucoma Laser Trial. I: acute effects of argon laser trabeculoplasty on intraocular pressure. Glaucoma Laser Trial Research Group. Arch Ophthalmol. 1989;107:1135-1142.

Thomas JV, Simmons RJ, Belcher D III. Argon laser trabeculoplasty in the presurgical glaucoma patient. Ophthalmology. 1982;89:187-197.

Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT), 6: treatment group differences in visual field changes. Am J Ophthalmol. 1995;120:10-22.

Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma, III: quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Ophthalmol. 1982; 100:135-146.

Robin AL, Pollack IP, House B, Enger C. Effects of ALO 2145 on intraocular pressure following argon laser trabeculoplasty. Arch Ophthalmol. 1987;105:646-650. Robin AL. Argon laser trabeculoplasty medical therapy to prevent the intraocular pressure rise associated with argon laser trabeculoplasty. Ophthalmic Surg. 1991;22: 31-37.

Chung HS, Shin DH, Birt CM, et al. Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes. Ophthalmology. 1997;104: 1921-1925.

Dapling RB, Cunliffe IA, Longstaff S. Influence of apraclonidine and pilocarpine alone and in combination on post laser trabeculoplasty pressure rise. Br J Ophthal-mol. 1994;78:30-32.

Birt CM, Shin DH, Reed SY, et al. One vs. two doses of 1.0% apraclonidine for prophylaxis of intraocular pressure spike after argon laser trabeculoplasty. Can J Oph-thalmol. 1995;30:266-269.

Holmwood PC, Chase RD, Krupin T, et al. Apraclonidine and argon laser trabeculoplasty. Am J Ophthalmol. 1992;114:19-22.

Threlkeld AB, Assalian AA, Allingham RR, Shields MB. Apraclonidine 0.5% versus 1% for controlling intraocular pressure elevation after argon laser trabeculoplasty. Ophthalmic Surg Lasers. 1996;27:657-660.

Rosenberg LF, Krupin T, Ruderman J, et al. Apraclonidine and anterior segment laser surgery: comparison of 0.5% versus 1.0% apraclonidine for prevention of postoperative intraocular pressure rise. Ophthalmology. 1995;102:1312-1318. Allf BE, Shields MB. Early intraocular pressure response to laser trabeculoplasty 180 degrees without apraclonidine versus 360 degrees with apraclonidine. Ophthalmic Surg. 1991;22:539-542.

Mittra RA, Allingham RR, Shields MB. Follow-up of argon laser trabeculoplasty: is a day-one postoperative IOP check necessary? Ophthalmic Surg Lasers. 1995;26:410-413.

Robin AL, Pollack IP. A comparison of neodymium:YAG and argon laser ir-idotomies. Ophthalmology. 1984;91:1011-1016.

Robin AL, Pollack IP, deFaller JM. Effects of topical ALO 2145 (p-aminoclonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy. Arch Ophthalmol. 1987;105:1208-1211.

Fernandez-Bahamonde JL, Alcaraz-Michelli V. The combined use of apraclonidine and pilocarpine during laser iridotomy in a Hispanic population. Ann Ophthalmol. 1990;22:446-449.

Blackwell C, Hirst LW, Kinnas SJ. Neodymium-YAG capsulotomy and potential blindness. Am J Ophthalmol. 1984;98:521-522.

Vine AK. Ocular hypertension following Nd:YAG laser capsulotomy: a potentially blinding complication. Ophthalmic Surg. 1984;15:283-284.

Kurata F, Krupin T, Sinclair S, Karp L. Progressive glaucomatous visual field loss after neodymium-YAG laser capsulotomy. Am J Ophthalmol. 1984;98:632-634. Cullom RD Jr, Schwartz LW. The effect of apraclonidine on the intraocular pressure of glaucoma patients following Nd:YAG laser posterior capsulotomy. Ophthalmic Surg Lasers. 1993;24:623-626.

Pollack IP, Brown RH, Crandall AS, et al. Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical 1% apra-clonidine. Arch Ophthalmol. 1988;106:754-757.

Nesher R, Kolker AE. Failure of apraclonidine to prevent delayed IOP elevation after Nd:YAG laser posterior capsulotomy. Trans Am Ophthalmol Soc. 1990;88: 229-236.

Yaldo MK, Shin DH, Parrow KA, et al. Additive effect of 1% apraclonidine hydrochloride to nonselective beta-blockers. Ophthalmology. 1991;98:1075-1078. Gordon RN, Liebmann JM, Greenfield DS, Lama P, Ritch R. Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy. Eye. 1998;12(pt 4):697-700.

Shin DH, Glover BK, Cha SC, et al. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. Am J Ophthalmol. 1999;127:511-515. Williams GC, Orengo-Nania S, Gross RL. Incidence of brimonidine allergy in patients previously allergic to apraclonidine. J Glaucoma. 2000;9:235-238. Burke JA, Potter DE. Ocular effects of a relatively selective alpha 2 agonist (UK-14,304-18) in cats, rabbits and monkeys. Curr Eye Res. 1986;5:665-676. David R, Spaeth GL, Clevenger CE, et al. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty. Arch Ophthalmol. 1993;111:1387-1390.

Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996;41(suppl 1):S27-S37. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997;115: 847-852.

LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing bri-monidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology. 1998; 105:1960-1967.

Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily. 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol. 1999; 127:20-26.

Katz LJ. Twelve-month evaluation of brimonidine-Purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119-126. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999; 128:8-14.

Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma. 2001;10:220-226.

Konstas AG, Karabatsas CH, Lallos N, et al. 24-hour intraocular pressures with brimonidine Purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology. 2005;112:603-608.

Akman A, Cetinkaya A, Akova YA, Ertan A. Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. Eye. 2005;19:145-151.

94. Zabriskie N, Netland PA. Comparison of brimonidine/latanoprost and timolol/ dorzolamide: two randomized, double-masked, parallel clinical trials. Adv Ther. 2003;20:92-100.

95. Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol. 1995;113:77-83.

96. Yuen NS, Cheung P, Hui SP. Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy. Jpn J Ophthalmol. 2005;49:89-92.

97. Chen TC. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery. Cataract Refract Surg. 2005;31:1707-1712.

98. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology. 1997;104:131-136.

99. Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther. 2001;23:604-619.

100. Wheeler LA, Gil DW, WoldeMussie E. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol. 2001;45(suppl 3):S290-S294.

101. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:2849-2855.

102. Yoles E, Wheeler LA, Schwartz M. a2-Adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci. 1999;40: 65-73.

103. Ruiz LC, Ruiz LA, Link B. Influence of topical brimonidine on visual field in glaucoma. Eur J Ophthalmol. 2001;11(suppl 2):S67-S71.

104. Tsai JC, Chang HW. Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study. J Ocul Pharmacol Ther. 2005;21:475-482.

This page intentionally left blank

Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook

Post a comment